Urinary Biomarker Real World Evaluation- Bladder Cancer Pathway

• Research type

  Research Study

• Full title

  Urinary Biomarker Real World Evaluation- Bladder Cancer Pathway (ARMADA- BCP)

• IRAS ID

  364053

• Contact name

  Jonathan Aning

• Contact email

  jonathan.aning@nbt.nhs.uk

• Sponsor organisation

  North Bristol NHS Trust

• Duration of Study in the UK

  1 years, 6 months, 30 days

• Research summary

  Bladder Cancer (BC) is the seventh most common cancer in Western Society with around 10,000 new BC cases registered per year in the UK. BC is not immediately life threatening, but up to 44% of patients with BC progress to a more serious type. This type of BC has a 27-50% 5yr survival rate. Outcomes for BC have not improved for over 25yrs, therefore it is important to research better diagnosis and treatment methods. This study looks at the tests patients have when they are sent to hospital for possible BC.
  When a patient has blood in their urine they go to hospital where they have their urine tested and have a test called a flexible cystoscopy. A small camera on a flexible tube is used to look inside the bladder. This can be quite uncomfortable and also means the patient has to visit the hospital to have it done. A new testing kit has been made that can check for BC by looking at biomarkers (small molecules) in patients urine. This study wants to see if it is practical and easy for patients to do a urine sample at home and post it back to the lab for testing. Patients referred to hospital with blood in their urine will be asked if they want to take part. They will have all their usual tests and appointments but also be provide a urine sample from home and post it (free) back to the lab. The research team will also check the patients notes to see the outcome of the hospital tests. This study is the first step in helping researchers learn if some patients can be checked for BC using this urine test without having a flexible cystoscopy.

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  25/EE/0280

• Date of REC Opinion

  24 Dec 2025

• REC opinion

  Further Information Favourable Opinion